ABSTRACT
BACKGROUND: Among the medications used to treat knee osteoarthritis (OA), oral patented crystalline glucosamine sulfate (pCGS) and platelet-rich plasma (PRP) have become popular alternatives to painkillers or nonsteroidal anti-inflammatory drugs (NSAIDs). Although studies have shown that pCGS and PRP improve clinical outcomes, no study has compared outcomes between these optional treatments. We compared functional performance outcomes from baseline to the 1-year follow-up (FU) between oral pCGS and PRP in patients with knee OA. MATERIALS AND METHODS: Three hundred eighty-two patients receiving oral pCGS and 122 patients receiving PRP injections were enrolled for a review of functional performance outcomes, including a five-time sit-to-stand test (5xSST), time up-and-go test (TUGT), and 3-minute walk distance test (3MWDT). The patients were followed up for one year. The pCGS group received 1500 mg daily, whereas the PRP group received 2 cycles of intra-articular injections at week 0 and week 6. Using propensity score matching based on age, sex, height, weight, BMI, and Kellgren and Lawrence (KL) classification, all three functional performance outcomes were compared between the baseline (pretreatment), 6-week, 12-week, 24-week, and 1-year FUs. RESULTS: With a ratio of 2:1 (pCGS: PRP), 204 patients in the pCGS group were matched with 102 patients in the PRP group. Compared with the baseline levels, the PRP group showed significant improvements in 5xSST and TUGT outcomes from 6 weeks and significant improvements in 3MWDT outcomes from 12 weeks, whereas the pCGS group showed significant improvements in TUGT outcomes from 6 weeks and significant improvements in 5xSST and 3MWDT outcomes from 12 weeks. At the 24-week and 1-year FU, both groups showed significant improvements in all three functional performance tests without adverse events. CONCLUSIONS: Although the PRP group showed faster improvements in 5xSST outcomes at six weeks, from the 12-week to 1-year FU, both the pCGS and PRP groups showed significant improvements in 5xSST, TUGT, and 3MWDT outcomes. As the use of PRP is more complicated and invasive than the use of oral pCGS, the benefits and drawbacks of selecting PRP over pCGS in knee OA treatment should be examined.
Subject(s)
Glucosamine , Osteoarthritis, Knee , Platelet-Rich Plasma , Propensity Score , Humans , Male , Female , Osteoarthritis, Knee/drug therapy , Osteoarthritis, Knee/therapy , Osteoarthritis, Knee/physiopathology , Glucosamine/therapeutic use , Glucosamine/administration & dosage , Middle Aged , Aged , Administration, Oral , Treatment Outcome , Physical Functional PerformanceABSTRACT
PURPOSE: To investigate the protective effect of intravesical glucosamine in treating overactive bladder (OAB). METHODS: Ninety-two female Sprague-Dawley (SD) rats were divided into 4 groups i.e. protamine sulfate (PS), N-acetylcysteine (NAC), and glucosamine-treated PS (GPS), and normal saline control (NC) were used. We induced hyperactivity in rats via intravesical infusion of PS and potassium chloride (KCl), whereas the NC group underwent a sustained intravesical saline infusion for 1 h. N-acetylcysteine (NAC), a potential antioxidant as well as anti-inflammatory agent was employed as positive control. Cystometrography (CMG) was then conducted to determine urodynamic parameters, i.e., leak point pressure (LPP, n = 48) and inter-contractile interval, the duration between two voids (ICI, n = 32). RESULTS: LPP was significantly elevated in the GPS group (mean ± SD: 110.9 ± 6.2 mmHg) compared to the NC (81.0 ± 32.5 mmHg), PS (40.3 ± 10.9 mmHg), and NAC group (70.3 ± 19.4 mmHg). The cystometrogram data also reveals a prolonged ICI in the GPS group (241.3 ± 40.2 s) compared to the NC group (216.0 ± 41.7 s), PS group (128.8 ± 23.6 s), and NAC group (193.8 ± 28.3 s). CONCLUSION: This preliminary study implies the ameliorative impact of GPS treatment on OAB in terms of improved urodynamic parameters, including LPP and ICI.
Subject(s)
Disease Models, Animal , Glucosamine , Potassium Chloride , Protamines , Rats, Sprague-Dawley , Urinary Bladder, Overactive , Animals , Urinary Bladder, Overactive/drug therapy , Female , Rats , Administration, Intravesical , Glucosamine/pharmacology , Glucosamine/therapeutic use , Glucosamine/administration & dosageABSTRACT
AIM: This study was aimed to assess the efficacy and safety of two oral Symptomatic Slow Acting Drugs for Osteoarthritis (SYSADOAs)-Glucosamine Sulfate, Chondroitin Sulfate, and their combination regimen in the management of knee osteoarthritis (KOA). METHODS: This systematic review was conducted according to PRISMA 2020 guidelines. A detailed literature search was performed from 03/1994 to 31/12/2022 using various electronic databases including PubMed, Embase, Cochrane Library, and Google Scholar, using the search terms-Glucosamine sulfate (GS), Chondroitin sulfate (CS), Knee osteoarthritis, Joint pain, Joint disease, and Joint structure, for literature concerning glucosamine, chondroitin, and their combination in knee osteoarthritis treatment. Cochrane Collaboration's Risk assessment tool (version 5.4.1) was used for assessing the risk of bias and the quality of the literature. The data was extracted from the included studies and subjected to statistical analysis to determine the beneficial effect of Glucosamine Sulfate, Chondroitin Sulfate, and their combination. RESULTS: Twenty-five randomized controlled trials (RCTs) were included in this systematic review. In short, exclusively 9 RCTs for GS, 13 RCTs for CS, and 3 RCTs for the combination of GS and CS. All these studies had their treatment groups compared with placebo. In the meta-analysis, CS showed a significant reduction in pain intensity, and improved physical function compared to the placebo; GS showed a significant reduction in tibiofemoral joint space narrowing. While the combination of GS and CS showed neither a reduction in pain intensity, nor any improvement in the physical function. However, the combination exhibited a non-significant reduction in joint space narrowing. In the safety evaluation, both CS and GS have shown good safety profile and were well tolerated. CONCLUSION: This meta-analysis revealed that the CS (with decreased pain intensity and improvement in the physical function), and GS (with significant reduction in the joint space narrowing) have significant therapeutic benefits. However, their combination did not significantly improve the symptoms or modify the disease. This may be due to the limited trials that are available on the combination of the sulfate forms of the intervention. Hence, there is a scope for conducting multicentric randomised controlled trials to evaluate and conclude the therapeutic role of CS and GS combination in the management of KOA.
Subject(s)
Chondroitin Sulfates , Drug Therapy, Combination , Glucosamine , Osteoarthritis, Knee , Randomized Controlled Trials as Topic , Chondroitin Sulfates/administration & dosage , Chondroitin Sulfates/adverse effects , Chondroitin Sulfates/therapeutic use , Humans , Osteoarthritis, Knee/drug therapy , Glucosamine/therapeutic use , Glucosamine/administration & dosage , Glucosamine/pharmacology , Treatment OutcomeABSTRACT
OBJECTIVE: To describe the effect of different substance combinations administered through mesotherapy in dogs with hip osteoarthritis. ANIMALS: 104 dogs. METHODS: In this retrospective study, 4 groups (dogs treated with a combination of lidocaine, piroxicam, and thiocolchicoside [MG]; dogs treated with lidocaine, piroxicam, and Traumeel [TG]; dogs treated with lidocaine, piroxicam, and glucosamine [GG]; and dogs treated with the same combination as in MG combined with a photobiomodulation session [MPG]) were set. For all groups, the same treatment frequency was followed. Response to treatment was measured with the Canine Brief Pain Inventory (divided into pain interference score and pain severity score), Liverpool Osteoarthritis in Dogs (LOAD), and Canine Orthopedic Index (divided into function, gait, stiffness, and quality of life) before treatment and 15, 30, 60, 90, and 120 days after treatment. Cox proportional hazard regression analysis was used to investigate the influence of treatment, age, sex, body weight, breed, and Orthopedic Foundation for Animals score. RESULTS: Dogs had a mean age of 7.6 ± 3.1 years and body weight of 28.6 ± 5.5 kg. Hip osteoarthritis was classified as mild (4), moderate (70), or severe (30). Greater improvements were observed in MG and MPG. Kaplan-Meier estimators showed MG and MPG had longer periods with clinically significant results. Treatment was the covariable that contributed more frequently to the outcomes observed. CLINICAL RELEVANCE: The combination used in MG, particularly combined with photobiomodulation, produced longer-lasting clinically significant results.
Subject(s)
Dog Diseases , Mesotherapy , Piroxicam , Animals , Dogs , Dog Diseases/drug therapy , Dog Diseases/therapy , Retrospective Studies , Male , Female , Piroxicam/therapeutic use , Piroxicam/administration & dosage , Piroxicam/analogs & derivatives , Mesotherapy/veterinary , Colchicine/therapeutic use , Colchicine/administration & dosage , Lidocaine/therapeutic use , Lidocaine/administration & dosage , Drug Therapy, Combination/veterinary , Osteoarthritis/veterinary , Osteoarthritis/drug therapy , Glucosamine/therapeutic use , Glucosamine/administration & dosage , Plant Extracts/therapeutic use , Plant Extracts/administration & dosage , Osteoarthritis, Hip/veterinary , Osteoarthritis, Hip/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Low-Level Light Therapy/veterinaryABSTRACT
Osteoarthritis (OA) is an age-related degenerative joint disease with a great impact on patients' well-being and quality of life. This is an observational, open, single-arm multicenter study aimed to evaluate the effectiveness of a nutritional supplement in patients with knee and/or hip OA. A total of 186 patients were recruited from Spanish centers and received a supplement containing hydrolyzed collagen (3000 mg), chondroitin sulfate (800 mg), glucosamine sulfate (700 mg), turmeric extract (250 mg) and devil's claw (150 mg), once daily during 6 months. The primary outcome was the patients' self-perceived pain in the affected joints measured with a visual analogue scale (VAS). Secondary outcome was the patient's functioning, measured with the Lequesne Functional Index and the Western Ontario and McMaster Universities Arthritis Index (WOMAC). Participants showed a significant reduction in self-perceived pain after 3 (mean reduction ± standard deviation, 1.99 ± 1.05) and 6 months (3.57 ± 1.39) of treatment (p < 0.0001 in both comparisons). Lequesne Functional Index score was significantly reduced at 3 months (3.86 ± 2.94) and at 6 months (6.73 ± 4.30) of treatment (p < 0.0001 in both comparisons). The WOMAC index was also significantly reduced after 3 (14.24 ± 10.04) and 6 months (26.43 ± 17.35) of treatment (p < 0.0001 in both comparisons). Significant reductions in WOMAC subdomains (p < 0.0001 in all comparisons) were observed. No severe adverse events were reported during the study. The main results arising from this study show that this nutritional supplementation can improve OA-related symptoms and physical function with a good safety profile in patients with hip and/or knee OA.
Subject(s)
Chondroitin Sulfates , Osteoarthritis, Knee , Humans , Chondroitin Sulfates/therapeutic use , Glucosamine/therapeutic use , Quality of Life , Dietary Supplements , Pain/drug therapy , Pain/complications , Osteoarthritis, Knee/drug therapy , Treatment Outcome , CollagenABSTRACT
Osteoarthritis in the temporomandibular joint (TMJ) is a chronic disease characterized by irreversible damage to articular surfaces, including inflammation, loss of articular cartilage, and subchondral bone alterations, which would be radiographically evident only in later stages. Symptomatic slow-acting so-called nutraceutical drugs have been proposed as a treatment for osteoarthritis in comparison to non-steroidal anti-inflammatory drugs (NSAID) because of their appreciable safety profile even in long-term intake. Glucosamine, being one among them, proved highly efficient in knee osteoarthritis. However, its application in TMJ osteoarthritis dates back only to 2001 and is still inconclusive in its efficiency even with systematic reviews, in restoring the structural and functional aspects of damaged TMJ. Glucosamine, being a natural compound and also a contributor to building the matrix of articular cartilage, can be utilized effectively for TMJ osteoarthritis as an adjunct along with other conventional treatment modalities available till now, which also have moderate prognosis in most of the clinical scenarios. This review summarizes data relating to the mechanism of osteoarthritis and its management using glucosamine formulations. The beneficial effects of glucosamine on the pathophysiology of TMJ osteoarthritis are possibly due to its contribution to hyaluronic acid regulation and in establishing a proper balance between anabolism/catabolism in the articular tissues.
Subject(s)
Glucosamine , Osteoarthritis , Humans , Glucosamine/therapeutic use , Osteoarthritis/drug therapy , Temporomandibular Joint Disorders/drug therapy , Temporomandibular Joint/drug effects , Temporomandibular Joint/metabolismABSTRACT
Tecnologia: Combinação de glicosamina e condroitina. Indicação: Tratamento de osteoartrite em adultos. Pergunta: O tratamento com a combinação de glicosamina e condroitina é mais eficaz e seguro que os demais tratamentos para osteoartrite disponíveis no SUS? Métodos: Uma revisão rápida de evidências, uma revisão de revisões sistemáticas, com levantamento bibliográfico realizado na base de dados PUBMED, utilizando estratégia estruturada de busca. A qualidade metodológica das revisões sistemáticas foi avaliada com AMSTAR-2. Resultados: Foi selecionada uma revisão sistemática, que atendiam aos critérios de inclusão. Conclusão: A combinação de glicosamina com condroitina, comparados ao placebo, mostrou ser mais eficaz para tratamento da dor e função e alcançou o segundo lugar nas alternativas terapêuticas para tratamento da dor e função
Technology: Combination of glucosamine and chondroitin. Indication: Treatment of osteoarthritis in adults. Question: Is the treatment with the combination of glucosamine and chondroitin more effective and safer than the other treatments for osteoarthritis available in the Brazilian Public Health System? Methods: A rapid review of evidence, a overview of systematic reviews, with bibliographic search done in PUBMED database, using a structured search strategy. The methodological quality of systematic reviews was assessed using AMSTAR-2. Results: A systematic review was selected, which met the inclusion criteria. Conclusion: The combination of glucosamine and chondroitin, compared to placebo, proved to be more effective for the treatment of pain and function and reached second place in therapeutic alternatives for the treatment of pain and function
Subject(s)
Humans , Male , Female , Osteoarthritis/drug therapy , Chondroitin/therapeutic use , Glucosamine/therapeutic use , Efficacy , Drug Combinations , Comparative Effectiveness Research , Systematic ReviewABSTRACT
Objetivo: El objetivo del estudio es evaluar si la desprescripción de medicamentos considerados de bajo valor intrínseco como los condroprotectores o SYSADOA, conlleva un empeoramiento sintomáti-co de la artrosis, incrementándose el consumo de analgésicos.Material y métodos: Siguiendo la práctica clínica habitual se retiró el tratamiento con SYSADOA a pa-cientes de un Centro de Atención Primaria (pobla-ción asignada: 34.382 habitantes, 17% mayores de 65 años) en base a la evidencia científica publicada y a la recomendación de la administración sanitaria de reducir los tratamientos con medicamentos de bajo valor intrínseco. Mediante un estudio obser-vacional post-intervención se analizaron diferen-cias de consumo de analgésicos y AINEs entre un periodo anterior a la retirada y el mismo periodo post-retirada.Resultados: Se analizaron 354 pacientes (68,4% mujeres, media de edad 66,2 años). No se encon-traron diferencias estadísticamente significativas en el consumo de analgesia total en el periodo de 6 meses post-retirada (media de 3,97 envases) com-parado con el periodo de 6 meses previo (media de 4,04 envases). Al estratificar por código ATC, edad y género, únicamente se encontraron diferencias en el consumo de otros analgésicos y antipiréticos teniendo en cuenta el sexo.Conclusión: Se concluye que, considerar con el paciente la desprescripción de SYSADOA a criterio del médico, es seguro y no conlleva un aumento del consumo de analgésicos (otros analgésicos y anti-piréticos, AINE, opioides menores, opioides mayo-res) sugiriendo que no implica un empeoramiento de la enfermedad artrósica. La desprescripción de SYSADOA, además, puede contribuir a reducir la po-limedicación sin alterar la situación clínica y evitar posibles riesgos de efectos adversos o interaccio-nes potenciales (AU)
Objective: The objective of this study is to assess if the deprescription of medications that are consid-ered low intrinsic value medications such as the chondroprotectors or SYSADOA entails a symptom-atic worsening of the arthrosis and consequently an increase of the consumption of analgesics.Material and Methods: Following the usual clinical practise, the SYSADOA treatment was withdrawn to the patients from a Primary Health Care Centre (assigned population: 34,382 inhabitants, 17% up to 65 years old) according to the published scientific proof and the recommendation of the health ad-ministration consisting of reducing the treatments with low intrinsic value medications. Differences in consumption of analgesics and AINEs between a previous period before the withdrawn and the same period post-withdrawn were studied through an observational post-intervention study.Results: 354 patients were analysed (68,4% wom-en, average age 66,2 years). There were not found significant differences from a statistical point of view in the total consumption of analgesia in the 6 months period post-withdrawn (average of 3,97 packagings) compared to the previous period of 6 months (average of 4,04 packagings). When stratifying by ATC code, age and gender, there were only found differences in the consumption of other analgesics and antipyretics taking into account the sex.Conclusion: It is concluded that considering togeth-er with the patient the deprescription of SYSADOA according to doctors criteria is safe and does not involve an increase of analgesics consumption (other analgesics, antipyretics, AINEs, major and minor opiods) suggesting that it does not suppose a worsening of the arthrosis disease. Besides, the deprescription of SYSADOA may contribute to re-duce polymedication without disrupting the clinical situation and avoid possible risks of adverse effects or potential interactions
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Joint Diseases/drug therapy , Analgesics/therapeutic use , Drug Misuse , Chondroitin/therapeutic use , Glucosamine/therapeutic use , Deprescriptions , Retrospective StudiesABSTRACT
Abstract Objectives: To compare the efficacy and safety of a new formulation of a fixed dose combination of glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg) versus the reference product (RP) in patients with knee osteoarthritis (OA). Methods: In this multicenter, randomized, single-blind trial, 627 patients with knee osteoarthritis (OA)—Kellgren-Lawrence grades 2 or 3 and mean score ≥ 40 mm in the WOMAC pain subscale—were randomized to receive GS/ CS or the RP for 24 weeks. The primary efficacy endpoint was the absolute change in WOMAC pain subscale score. The secondary endpoints included the following: WOMAC total and subscale scores, overall assessment of the disease by the patient and the investigator, SF-12 score, OMERACT-OARSI response rate to the treatment, and rescue medication use. Results: Mean reductions of WOMAC pain score were - 35.1 (sd = 23.2) mm in the GS/CS group and - 36.5 (sd = 24.9) mm in the RP group. The difference between the adjusted means of both treatments confirmed the noninferiority of GS/CS versus the RP. Improvement was observed in pain, stiffness, physical function and total WOMAC score, as well as in overall OA assessment by the patient and the investigator for both groups. No improvement was observed in SF-12. The rate of OMERACT-OARSI responders was 89.4% in GS/CS group and 87.9% in the RP group. Headache and changes in glucose tolerance were the most frequent treatment-related adverse events. Conclusions: The new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin sulfate was non-inferior to the RP in symptomatic treatment of knee OA, with a high responder rate and good tolerability profile. Trial registration: ClinicalTrials.gov; Registration number NCT02830919; Date of registration: July 13, 2016; First randomization date: December 05, 2016).(AU)
Subject(s)
Humans , Chondroitin/therapeutic use , Osteoarthritis, Knee/drug therapy , Drug Combinations , Glucosamine/therapeutic use , Single-Blind Method , Treatment OutcomeABSTRACT
RESUMEN En abril de 2016, el Instituto Nacional de Servicios Sociales para Jubilados y Pensionados excluyó del subsidio social la cobertura al 100% de 159 fármacos, entre ellos, los antiartrósicos sintomáticos de acción lenta o symptomatic slow-acting drugs for osteoarthritis (SySADOA), por insuficiente evidencia de beneficio clínico significativo. Evaluamos el efecto de esta medida sobre la utilización de SySADOA y de los antiinflamatorios no esteroides (AINE), no afectados por la medida. Se compararon las dispensas ambulatorias de los SySADOA y los AINE de 2015 a 2017, midiendo unidades dispensadas, precio de venta al público y gasto de bolsillo del beneficiario para cada mes. Luego de la medida, descendieron un 61,6% los envases de SySADOA dispensados y un 63,4% el monto total del precio de venta al público, medido en valores constantes. La dispensa no se reorientó hacia los AINE, que descendieron un 6,1%. Disminuyó tanto la incidencia de nuevos tratamientos (de 6,4 a 3,3 tratamientos por 1.000 beneficiarios por mes) como su continuidad. El gasto de bolsillo de los beneficiarios en SySADOA aumentó un 75,8% (a valores constantes). La desinversión en intervenciones de valor terapéutico cuestionable es una herramienta valiosa para la sustentabilidad de los sistemas de salud.
ABSTRACT In April 2016, the National Institute of Social Services for Retirees and Pensioners discontinued its policy of 100% coverage for 159 drugs (the "social subsidy"), including symptomatic slow-acting drugs for osteoarthritis (SYSADOAs), due to insufficient evidence of significant clinical benefit. We evaluated the effect of this measure on the use of SYSADOAs as well as non-steroidal anti-inflammatory drugs (NSAIDs), which were unaffected by this policy change. We compared outpatient dispensations of SYSADOAs and NSAIDs from 2015 to 2017, measuring dispensed units, retail price, and out-of-pocket expenses for beneficiaries each month. After the change in coverage, there was a 61.6% total decrease in SYSADOA units dispensed, and a 63.4% decrease in the final sales price to the public, measured in constant values. Dispensation was not reoriented towards NSAIDs, which fell by 6.1%. The incidence of new treatments decreased (from 6.4 to 3.3 treatments per 1,000 beneficiaries per month), as did their continuity. Beneficiaries' out-of-pocket spending on SYSADOAs increased by 75.8% (at constant values). Disinvestment in interventions with questionable therapeutic value is an important tool in working toward the sustainability of health systems.
Subject(s)
Humans , Osteoarthritis/drug therapy , Pharmaceutical Preparations , Argentina , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Glucosamine/therapeutic useABSTRACT
OBJETIVO: Revisar la evidencia reciente disponible sobre la eficacia del empleo de los SYSADOA (Symptomatic Slow Acting Drugsfor Osteoarthritis) en artrosis, como estrategia terapéutica que pudiera adaptarse mejor a la etiología de la enfermedad como al paciente por su elevada seguridad y tolerabilidad. Metodología: Se ha realizado una búsqueda bibliográfica de la literatura publicada hasta 30 de agosto de 2019 en PubMed, las palabras clave empleadas en la búsqueda fueron:"evidence", "clinical trials", "osteoarthritis", "management", "chondroitin" y "glucosamine". Se revisaron guías médicas internacionales, estudios epidemiológicos y fichas técnicas de medicamentos de la Agencia Española del Medicamento y Productos Sanitarios. RESULTADO: Se identificaron un total de154 artículos con los algoritmos de búsqueda empleados orientados a valorar la evidencia de este grupo terapéutico como el impacto económico y sanitario generado por la artrosis. Tras la lectura de títulos y resúmenes se procedió al descarte de 82 artículos por no adaptarse al objetivo del presente trabajo. Se realizó una segunda selección valorando la calidad metodológica y contenido. Finalmente se escogieron 8 artículos. También se consultaron las fichas técnicas de los fármacos involucrados como guías médicas y estudios epidemiológicos como el EPISER. Los últimos estudios muestran una tendencia favorable a los SYSADOA como alternativa al consumo continuado de AINE (Antiinflamatorios No Esteroideos), mostrándose una eficacia comparable al celecoxib, tanto en combinación en el estudio MOVES, como por separado en el estudio CONCEPT, ambos en 2017. CONCLUSIÓN: La elevada prevalencia de la artrosis y los inconvenientes derivados de su manejo tradicional hacen necesario el empleo de alternativas terapéuticas. Los SYSADOA se postulan como una herramienta que pudiera adaptarse mejor a la enfermedad por su carácter crónico, y al tipo de paciente al que frecuentemente van dirigidas estas terapias. Sin embargo, la disparidad obtenida en los ensayos clínicos dificulta alcanzar un consenso y ponen de manifiesto la necesidad de aclarar la confianza depositada en ellos
OBJECTIVE: To review the available recent evidence about the effectiveness of the usage of SYSADOA (Symptomatic Acting Drugsfor Osteoarthritis) in osteoarthritis, as a therapeutic strategy that could evolve with the etiology of the disease and the patient thanks toits high security and tolerability. METHODS: It was carried out a bibliographical research of the published literature until 30th August 2019 in PubMed. The key words employed in the search were: "evidence", "clinical trials", "osteoarthritis", "management", "chondroitin" and "glucosamide". International medical guides, epidemiologic studies and data sheets of drugs from The Spanish Agency for Medication and Healthcare Products (AEMPS) were examined. RESULTS: A total of 154 articles were identified with the search algorithms used, orientated to evaluate the evidence of this therapeutic group as well as the economic and health impact generated by the osteoarthritis. After having read titles and abstracts, 82 articles were dismissed because they did not fit in the objective of the present work. A second selection was done taking into account the methodological quality and the content. In the end, 8 articles were chosen. The data sheets of the involved drugs together with the medical guides, the epidemiology studies and the EPISER were checked. The last studies show a favorable tendency to the SYSADOA as an alternative to the continued consume of non-steroidal anti-inflammatories. It was shown effectiveness comparable to celecoxib in combination with the study MOVES but also separately in the study CONCEPT, both in 2017. CONCLUSION: The high prevalence of osteoarthritis and the disadvantages derived from its traditional management make the usage of therapeutic alternatives necessary. The SYSADOA postulate as a key that could adapt better to the disease because of its chronic character and the kind of patient to whom are commonly targeted these therapies. Nevertheless, the disparity obtained in the clinical trials makes difficult to reach a consensus and reveals the necessity of clarifying the confidence placed in them
Subject(s)
Humans , Joint Diseases/drug therapy , Glucosamine/therapeutic use , Chondroitin Sulfates/therapeutic use , Anthraquinones/therapeutic use , Disease Management , Treatment Outcome , Reproducibility of ResultsABSTRACT
Abstract Glucosamine is known as anti-inflammatory, antioxidant and as neuroprotective as well as using to treat many of diseases. This work aimed to investigate the remedial effect of glucosamine (20mg/kg b.wt) against the damage induced by a single dose of γ-radiation (8Gy) or aluminium chloride (AlCl3) (100mg/kg b.wt) in the heart and brain tissues of female rats. Serum aspartate aminotransferase (AST), cholesterol, triglycerides (TGs), LDH and creatine kinase (CPK) were measured. Moreover, gene expression of amyloid protein precursor (APP) and seladin-1 were estimated in the brain tissue. Also, acetylcholinesterase activity (AChE) and p-tau protein expression were estimated in brain homogenate. Metallothioneine (MT) was estimated in the heart and brain tissues. Heart and brain histopathological examination was performed. Irradiation significantly decreased serum AST, CPK and LDH, as well as MT levels in heart and brain tissues. Also, gene expression of seladin-1 decreased. On the other hand, irradiation significantly increased serum TGs level and brain AchE activity, tau protein, and β-amyloid percursor (APP). AlCl3 administration (21 days) induced disturbance in most of the estimated parameters, especially AST, TGs, and MT. Glucosamine treatment with irradiation or AlCl3 improved most of the measured parameters. In addition, histopathological examination confirmed the biochemical results. In conclusion: Glucosamine could be used to improve the heart and brain damages induced by γ-radiation exposure or AlCl3.
Subject(s)
Animals , Female , Rats , Brain Diseases/drug therapy , Cardiovascular Diseases/drug therapy , Radiation Exposure/adverse effects , Aluminum Chloride/adverse effects , Glucosamine/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Brain Diseases/etiology , Brain Diseases/pathology , Cardiovascular Diseases/etiology , Cardiovascular Diseases/pathology , Polymerase Chain Reaction , Rats, Wistar , Disease Models, AnimalABSTRACT
OBJECTIVES: This study aimed to provide evidence for understanding how to treat osteoarthritis (OA) in our country. Therefore, it was necessary to match information and investigations related to the treatment of the disease from the three main types of specialists involved: physiatrists, orthopedists and rheumatologists. METHODS: The authors acted as a scientific advisory committee. From the initial discussions, a structured questionnaire was developed for use with a group of specialists on OA using the Delphi technique. The questionnaire was sent to 21 experts appointed by the authors, and the results obtained were critically analyzed and validated. RESULTS: The prevalence of OA was 33% in Brazil, corresponding to one-third of the individuals in the reference population, which included individuals over 25 years of age. Another significant finding was that most patients did not receive any form of treatment in the early stages of OA. CONCLUSION: The committee pointed to the need for early intervention and that the available medicinal resources can fulfil this important role, as is the case with SYSADOA treatments. Glucosamine-based medicinal products with or without chondroitin could also fulfill this need for early treatment. The other generated evidence and included investigations were then grouped together and are the subject of this publication.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Osteoarthritis/therapy , Delphi Technique , Clinical Competence/standards , Evidence-Based Medicine/standards , Orthopedics/standards , Osteoarthritis/drug therapy , Physical and Rehabilitation Medicine/standards , Severity of Illness Index , Brazil , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Chondroitin Sulfates/therapeutic use , Treatment Outcome , Osteoarthritis, Knee/therapy , Consensus , Drug Therapy, Combination , Glucosamine/therapeutic useABSTRACT
Estas historias de la LIBRETA DE VIAJE DEL MÉDICO DE FAMILIA, que forman una biblioteca del médico caminante o viajero emocional, son hojas sueltas en las que se escribe sobre paisajes y emociones; son un atlas de geografía emocional. La evocación de un paisaje ante la asistencia a un paciente -montañas, ríos, valles, playas, mares, desiertos, mesetas, islas, pantanos, cascadas, dunas, bosques, salinas, lagos, etc.-, con las sensaciones sentidas por el médico, de calor, frescor, humedad, dificultad, agobio, serenidad, inmensidad, soledad, etc. No es un diario, sólo una libreta de apuntes con las vivencias del médico sobre los patrones y procesos de la consulta en un cierto caso clínico, que a su vez, puede ilustrar un prototipo de esa clase de casos (AU)
These stories of the THE FAMILY PHYSICIANS TRAVEL NOTEBOOK, which form a library of the walking doctor or emotional traveler, are loose-leaf pages with writings about landscapes and emotions; they are an atlas of emotional geography. The evocation of a landscape before attending a patient -mountains, rivers, valleys, beaches, seas, deserts, plateaus, islands, swamps, waterfalls, dunes, forests, salt marshes, lakes, etc.-, with the sensations felt by the doctor -heat, coolness, humidity, hardship, stress, serenity, vastness, loneliness, etc. It is not a diary, only a notebook with the doctor's experiences about the patterns and processes of consultation in a clinical case, which in turn may illustrate a prototype for this type of cases (AU)
Subject(s)
Humans , Female , Aged , Travel , Travelers' Health , Expeditions , Family Practice/methods , Osteoarthritis, Knee/drug therapy , Travel Medicine/methods , Travel Medicine/organization & administration , Geography , Family Practice/trends , Glucosamine/therapeutic use , Travel Medicine/historyABSTRACT
No disponible
Subject(s)
Humans , Osteoarthritis/epidemiology , Metabolic Diseases/complications , Comorbidity , Disease Progression , Chondroitin Sulfates/therapeutic use , Glucosamine/therapeutic use , Anti-Inflammatory Agents/therapeutic useABSTRACT
ANTECEDENTES: La osteoartrosis es la enfermedad más común del sistema músculo-esquelético y constituye la principal causa de discapacidad o invalidez de todas las enfermedades crónicas. Desde 1990 surgen agentes "condromoduladores", muchos de venta libre, con discutido valor terapeútico y creciente demanda inducida por el complejo médico industrial. OBJETIVO: Evaluar la eficacia y seguridad de la Glucosamina y de la combinación Glucosamina y Condroitín sulfato en el tratamiento de la osteoartrosis. MÉTODO: Revisión sistemática donde se incluyeron 11 revisiones sistemáticas y metaanálisis, de 106 elegibles, publicados entre 2000 y 2015, con los siguientes puntos finales primarios: dolor evaluado por diferentes escalas, función, rigidez y eventos adversos; puntos finales secundarios: disminución del ancho del espacio articular, evaluación global del paciente y evaluación global del médico. RESULTADOS: Para los puntos finales primarios, las revisiones que ajustaron por sesgos y estratificaron por cada uno de ellos: ICCAs de alta calidad, el ocultamiento y el enmascaramiento adecuado, el análisis por intención de tratar, la independencia de la financiación de la industria y el mayor tamaño de la muestra, observaron un tamaño del efecto de moderado a leve o nulo (índice de Cohen de 0.0 a 0.5) en los grupos tratados con glucosamina o glucosamina-condroitín asociados, cuando se los comparó con placebo o AINES. Otras debilidades metodológicas fueron las diferencias en el periodo de seguimiento entre los participantes, las dosis y vías de administración, el tipo de preparaciones de glucosamina y sesgos de publicación. Esto genera eterogeneidad entre los estudios primarios con un elevado índice de inconsistencia, que tiene potencialidad para desviar la medida común de resultados de los MA. CONCLUSIONES: Para los puntos finales primarios, no hubo diferencias significativas de eficacia al comparar el sulfato de glucosamina contra placebo, aunque parecería mejorar su efecto si está asociada al condroitín sulfato. Tampoco se encontraron diferencias cuando se comparó la glucosamina o su asociación a condroitín sulfato con AINES. Los eventos adversos de la glucosamina, ya sea administrada sola o en combinación al condroitín sulfato, son más infrecuentes y menos serios que los que presentan los AINEs, pero aún no está claro si modifica el metabolismo de la glucosa. El clorhidrato de glucosamina no es efectivo por vía oral. Las evidencias muestran que el efecto de estos compuestos sobre el dolor y la funcionalidad articular es, nulo o leve, por lo que su valor en la clínica es limitado y no agregan valor terapéutico al tratamiento de la osteoartrosis.(AU)
Subject(s)
Humans , Osteoarthritis/drug therapy , Chondroitin/therapeutic use , Glucosamine/therapeutic use , Technology Assessment, Biomedical , Cost-Benefit Analysis , Drug CombinationsABSTRACT
No disponible
Subject(s)
Humans , Osteoarthritis/economics , Osteoarthritis/epidemiology , Osteoarthritis/prevention & control , Chondroitin/economics , Chondroitin/therapeutic use , Glucosamine/economics , Glucosamine/therapeutic use , Acetaminophen/adverse effects , Acetaminophen/therapeutic use , Glycosaminoglycans/economics , Glycosaminoglycans/therapeutic useABSTRACT
Chondroitin and glucosamine sulfate nutraceuticals are commonly used in the management of degenerative articular disease in veterinary routine. However, there are controversies on the contribution of these substances to articular cartilage. The purpose of this study was to evaluate the efficiency of a chondroitin and glucosamine sulfate-based veterinary nutraceutical on the repair of an induced osteochondral defect in a dog femoral condyle, by macroscopic, histological and histomorphometric analyses. The nutraceutical was orally administered the day following injury induction, every 24 hours (treated group, TG, n=24), compared with animals that did not receive the product (control group, CG, n=24). Six animals per group were anaesthetized for sample collection at 15, 30, 60 and 90 days after surgery. At 15 days, defects were macroscopically filled with red-pinkish tissue. After 30 days, whitish color tissue was observed, both in TG and CG animals, with firmer consistency to touch at 60 and 90 postoperative days. Histological analysis demonstrated that, in both groups, there was initial blood clot formation, which was subsequently substituted by a fibrin net, with capillary proliferation from the adjacent bone marrow and infiltration of mesenchymal cells in clot periphery. As cellular differentiation developed, repair tissue presented a fibrocartilage aspect most of the time, and new subchondral bone formation occurred in the deepest area corresponding to the defect. Histomorphometry suggested that the nutraceutical did not favor the articular cartilage repair process. It was concluded that nutraceutical did not significantly influence chondrocytes proliferation or hyaline architecture restoration.(AU)
Os nutracêuticos compostos de sulfato de condroitina e glucosamina são comumente utilizados no manejo da doença articular degenerativa na rotina veterinária. Entretanto, existem controvérsias sobre a contribuição dessas substâncias à cartilagem articular. O objetivo deste trabalho foi avaliar a eficácia de um nutracêutico veterinário à base de sulfato de condroitina e glucosamina na reparação de defeitos osteocondrais induzidos no côndilo femoral de cães, através de análises macroscópica, histológica e histomorfométrica. O nutracêutico foi administrado no dia seguinte à indução da lesão, pela via oral, a cada 24 horas (grupo tratado - GT, 24 animais), sendo comparado a animais que não receberam o produto (grupo controle - GC, de igual número de animais). Aos 15, 30, 60 e 90 dias após a cirurgia, seis animais por grupo foram anestesiados para ser realizada a coleta das amostras. Aos 15 dias, os defeitos eram macroscopicamente preenchidos por tecido de coloração rósea a avermelhada. Já a partir dos 30 dias, observou-se preenchimento por tecido de coloração esbranquiçada, tanto nos animais do GT quanto nos do GC, com consistência mais firme ao toque digital aos 60 e 90 dias de pós-operatório. A análise histológica revelou que, em ambos os grupos, houve inicialmente formação de coágulo sanguíneo que, posteriormente, foi substituído por uma rede de fibrina, com proliferação de capilares a partir da medula óssea adjacente e infiltração de células mesenquimais na periferia do coágulo. À medida que se processou a diferenciação celular, o tecido de reparação se apresentou na maioria das vezes com aspecto de fibrocartilagem e, na região mais profunda da área correspondente ao defeito, ocorreu formação de osso novo subcondral. A histomorfometria sugeriu que o nutracêutico não favoreceu o processo de reparação da cartilagem articular. Concluiu-se que o nutracêutico não influenciou consideravelmente na proliferação de condrócitos nem na restauração da arquitetura hialina.(AU)
Subject(s)
Animals , Dogs , Osteoarthritis/veterinary , Cartilage Diseases/veterinary , Chondroitin Sulfates/therapeutic use , Arthroplasty, Subchondral/veterinary , Glucosamine/therapeutic use , Joint Diseases/veterinaryABSTRACT
No disponible